These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27914633)

  • 1. What Can Big Data Offer the Pharmacovigilance of Orphan Drugs?
    Price J
    Clin Ther; 2016 Dec; 38(12):2533-2545. PubMed ID: 27914633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.
    Trifirò G; Sultana J; Bate A
    Drug Saf; 2018 Feb; 41(2):143-149. PubMed ID: 28840504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filtering big data from social media--Building an early warning system for adverse drug reactions.
    Yang M; Kiang M; Shang W
    J Biomed Inform; 2015 Apr; 54():230-40. PubMed ID: 25688695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mining Adverse Drug Reactions in Social Media with Named Entity Recognition and Semantic Methods.
    Chen X; Deldossi M; Aboukhamis R; Faviez C; Dahamna B; Karapetiantz P; Guenegou-Arnoux A; Girardeau Y; Guillemin-Lanne S; Lillo-Le-Louët A; Texier N; Burgun A; Katsahian S
    Stud Health Technol Inform; 2017; 245():322-326. PubMed ID: 29295108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The challenges of pharmacoepidemiology of orphan drugs in rare diseases.
    Lapeyre-Mestre M
    Therapie; 2020 Apr; 75(2):215-220. PubMed ID: 32164974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social Media Listening for Routine Post-Marketing Safety Surveillance.
    Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
    Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
    Hirota S; Yamaguchi T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The usefulness of listening social media for pharmacovigilance purposes: a systematic review.
    Convertino I; Ferraro S; Blandizzi C; Tuccori M
    Expert Opin Drug Saf; 2018 Nov; 17(11):1081-1093. PubMed ID: 30285501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country.
    Nguyen KD; Nguyen PT; Nguyen HA; Roussin A; Montastruc JL; Bagheri H; Olsson S
    Drug Saf; 2018 Feb; 41(2):151-159. PubMed ID: 28975584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
    Crisafulli S; Sultana J; Ingrasciotta Y; Addis A; Cananzi P; Cavagna L; Conter V; D'Angelo G; Ferrajolo C; Mantovani L; Pastorello M; Scondotto S; Trifirò G
    Expert Opin Drug Saf; 2019 Jun; 18(6):497-509. PubMed ID: 31059293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies.
    Koutkias VG; Lillo-Le Louët A; Jaulent MC
    Expert Opin Drug Saf; 2017 Feb; 16(2):113-124. PubMed ID: 27813420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting Social Media for Active Pharmacovigilance: The PVClinical Social Media Workspace.
    Kakalou C; Dimitsaki S; Dimitriadis VK; Natsiavas P
    Stud Health Technol Inform; 2022 Jun; 290():739-743. PubMed ID: 35673115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug safety and big clinical data: Detection of drug-induced anaphylactic shock events.
    Bouzillé G; Osmont MN; Triquet L; Grabar N; Rochefort-Morel C; Chazard E; Polard E; Cuggia M
    J Eval Clin Pract; 2018 Jun; 24(3):536-544. PubMed ID: 29532572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in perspective: drug withdrawals, data mining and policy implications.
    Alomar M; Palaian S; Al-Tabakha MM
    F1000Res; 2019; 8():2109. PubMed ID: 32161643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mining in Twitter for adverse events from malaria drugs: the case of doxycycline.
    Duval FV; Silva FABD
    Cad Saude Publica; 2019 May; 35(5):e00033417. PubMed ID: 31141025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014.
    Awodele O; Ibrahim A; Orhii P
    Int J Risk Saf Med; 2016 Mar; 28(1):13-23. PubMed ID: 27176753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance?
    Bagheri H; Lacroix I; Guitton E; Damase-Michel C; Montastruc JL
    Therapie; 2016 Apr; 71(2):235-9. PubMed ID: 27080844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.